Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	SEK 12.30	-1.99%	2,123
05/08/26	SEK 12.55	+0.40%	598
04/08/26	SEK 12.50	+3.73%	2,969
03/08/26	SEK 12.05	-1.63%	15,654
31/07/26	SEK 12.25	-5.77%	5,991

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 19:00:00 06/08/2026 +03			5-day change	1st Jan Change
12.30 ^SEK	-1.99%		-5.38%	-37.88%

07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW

Market Cap	88.59M 9.32M 8.09M 7.57M 6.93M 13.08M 888M 13.25M 34.77M 444M 34.99M 34.23M 1.48B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	88.59M 9.32M 8.09M 7.57M 6.93M 13.08M 888M 13.25M 34.77M 444M 34.99M 34.23M 1.48B	EV / Sales 2026 *	1.17x	EV / Sales 2027 *	-
Free-Float	42.81%	Yield 2026 *	-	Yield 2027 *	-

07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI
04-23	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Annexin Pharmaceuticals AB Provides Update on ANXV Clinical Study in Retinal Vein Occlusion and Diabetic Retinopathy	CI
04-13	Annexin Pharmaceuticals Mulls SEK20 Million Rights Issue; Bridge Facility Secured	MT
04-13	Annexin secures financing through bridge loan facility, plans rights issue	RE

07-21	Annexin updates on nine patients treated in NEXUS study	AQ
07-03	Annexin's rights issue 98 percent subscribed	AQ
06-23	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ
06-15	The subscription period in Annexin Pharmaceuticals’ rights issue begins today	AQ
06-10	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue	AQ

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news : Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Course Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	-1.99%
1 week	-5.38%
Current month	+0.41%
1 month	-1.20%
3 months	-20.39%
6 months	-22.64%
Current year	-37.88%

1 week	11.45	12.65
1 month	11.45	13.25
Current year	11.05	23.6
1 year	11.05	35.2
3 years	11.05	99.8
5 years	11.05	225
10 years	11.05	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	-1.99%	-5.38%	-59.54%	-84.96%	9.34M
WUXI APPTEC CO., LTD.	-3.25%	+12.81%	+52.96%	+88.86%	64.9B
ARGENX SE	+0.69%	+0.96%	+29.39%	+70.50%	54.05B
BIONTECH SE	-2.30%	-3.09%	-19.16%	-8.65%	23.16B
INSMED INCORPORATED	+30.89%	+28.12%	+16.87%	+494.56%	21.46B
WUXI BIOLOGICS (CAYMAN) INC.	+1.87%	+5.08%	+29.88%	-7.94%	21.25B
GENMAB A/S	-0.79%	+1.79%	+36.31%	-26.13%	17.94B
PHARMAESSENTIA CORPORATION	-3.37%	+19.44%	+211.98%	+369.13%	17.03B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.29%	+2.09%	+17.32%	+586.49%	14.99B
EXELIXIS, INC.	-5.59%	-4.50%	+41.74%	+163.95%	14.25B
Average	+1.93%	+2.91%	+35.78%	+164.58%	24.9B
Weighted average by Cap.	+1.49%	+3.64%	+42.94%	+147.62%

	2026 *	2027 *
Net sales	75.6M 7.95M 6.9M 6.46M 5.91M 11.16M 758M 11.31M 29.67M 378M 29.86M 29.21M 1.26B	-
Net income	19.6M 2.06M 1.79M 1.68M 1.53M 2.89M 196M 2.93M 7.69M 98.13M 7.74M 7.57M 327M	-58M -6.1M -5.29M -4.96M -4.54M -8.56M -581M -8.67M -22.76M -290M -22.91M -22.41M -966M
Net Debt	-	-